Intensity Therapeutics rockets on positive INT230-6 data
Shares of Intensity Therapeutics (Nasdaq: INTS) skyrocketed 120% to $8.79 pre-market today, after it announced positive safety, tolerability, efficacy and immune activation data from the company’s Phase II INVINCIBLE trial of INT230-6 in patients with early-stage breast cancer without chemotherapy during the 2023 San Antonio Breast Cancer Symposium.
The trial showed that:
- INT230-6 demonstrated a systemic increase in the median diversity of T-cell repertoire in patients’ blood compared to baseline that was also much larger than a control saline injection.
- A single injection of INT230-6 demonstrated an increase in CD4 T-cells up to >95% necrosis of a tumor.
- INT230-6 demonstrated an increase in CD4 T-cells ad NK cells within tumors.
- Gene expression profiling revealed treatment effect of up-regulation of immune pathways expressed by T-cell activation, lymphocyte activation and inflammatory responses.
- INT230-6 demonstrated a favorable safety profile and was well tolerated.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze